Description
INCB0123667 is an experimental drug currently being studied in clinical trials for advanced solid tumors, including colorectal cancer. It is being investigated as a potential treatment option, either alone (monotherapy) or in combination with other cancer drugs. The trials are in the early phase (Phase 1), primarily focused on determining the safe dosage, how the drug is processed by the body (pharmacokinetics), its effects on the body (pharmacodynamics), and whether it shows early signs of effectiveness (preliminary efficacy). These trials are open-label, meaning both the researchers and participants know who is receiving the drug. The trials are recruiting participants with advanced or metastatic solid tumors, including those with HER2 mutations. The specific role of INCB0123667 in colorectal cancer treatment is still under investigation.
Mechanism of Action
INCB0123667 is being studied to understand its effects on cancer cells. The specific way it works (its mechanism of action) is being investigated in clinical trials. Researchers are evaluating how it interacts with the body and its potential impact on tumor growth and spread.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.